Use of Pegvisomant in acromegaly. An Italian Society of Endocrinology guideline

Journal of Endocrinological Investigation

Volumn 37, Issue 10, 2014, Pages 1017-1030

  Giustina, A ^a   Ambrosio, M R ^b   Beck Peccoz, P ^c   Bogazzi, F ^d   Cannavo', S ^e   De Marinis, L ^f   De Menis, E ^g   Grottoli, S ^h   Pivonello, R ⁱ  

^a UNIVERSITY OF BRESCIA   (Italy)

^b UNIVERSITY OF FERRARA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF MESSINA   (Italy)

^f FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^g Ospedale Civile di Montebelluna   (Italy)

^h UNIVERSITY OF TURIN   (Italy)

ⁱ UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Acromegaly; Growth hormone; IGF 1; Pegvisomant; Somatostatin analogs

Indexed keywords

CABERGOLINE; GROWTH HORMONE; HEMOGLOBIN A1C; PEGVISOMANT; SOMATOSTATIN RECEPTOR; GROWTH HORMONE RECEPTOR; HUMAN GROWTH HORMONE;

ACROMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GLUCOSE METABOLISM; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; IMPAIRED GLUCOSE TOLERANCE; INJECTION SITE REACTION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID METABOLISM; OUTCOME ASSESSMENT; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SIDE EFFECT; TOXIC HEPATITIS; TUMOR GROWTH; TUMOR VOLUME; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ENDOCRINOLOGY; ITALY; STANDARDS;

ACROMEGALY; ENDOCRINOLOGY; HUMAN GROWTH HORMONE; HUMANS; ITALY; PRACTICE GUIDELINES AS TOPIC; RECEPTORS, SOMATOTROPIN;

EID: 84924403252     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/s40618-014-0146-x     Document Type: Review

References (116)

1. Melmed S, Colao A, Barkan A, Molitch M, Grossman AB, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance ML, Ho K, Giustina A, Acromegaly Consensus Group (2009) Guidelines for acromegaly management: an update. J Clin Endocrinol Metab 94:1509-1517
2. Melmed S, Casanueva F, Cavagnini F, Chanson P, Frohman LA, Gaillard R, Ghigo E, Ho K, Jaquet P, Kleinberg D, Lamberts S, Laws E, Lombardi G, Sheppard MC, Thorner M, Vance ML, Wass JA, Giustina A (2005) Consensus statement: medical management of acromegaly. Eur J Endocrinol 153:737-740
3. Giustina A, Chanson P, Kleinberg D, Bronstein MD, Clemmons DR, Klibanski A, van der Lely AJ, Strasburger CJ, Lamberts SW, Ho KK, Casanueva FF, Melmed S (2014) A consensus on the medical treatment of acromegaly. Nat Rev Endocrinol 10:243-248
4. Melmed S (2009) Acromegaly pathogenesis and treatment. J Clin Invest 119:3189-3202
5. Giustina A, Bronstein MD, Casanueva FF, Chanson P, Ghigo E, Ho KK, Klibanski A, Lamberts S, Trainer P, Melmed S (2011) Current management practices for acromegaly: an international survey. Pituitary 14:125-133
6. Giustina A, Casanueva FF, Cavagnini F, Chanson P, Clemmons D, Frohman LA, Gaillard R, Ho K, Jaquet P, Kleinberg DL, Lamberts SW, Lombardi G, Sheppard M, Strasburger CJ, Vance ML, Wass JA, Melmed S, Pituitary Society and the European Neuroendocrine Association (2003) Diagnosis and treatment of acromegaly complications. J Endocrinol Invest 26:1242-1247
7. Melmed S, Casanueva FF, Klibanski A, Bronstein MD, Chanson P, Lamberts SW, Strasburger CJ, Wass JA, Giustina A (2013) A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 16:294-302
8. Holdaway IM, Bolland MJ, Gamble GD (2008) A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly. Eur J Endocrinol 159:89-95
9. Giustina A, Barkan A, Casanueva FF, Cavagnini F, Frohman L, Ho K, Veldhuis J, Wass J, Von Werder K, Melmed S (2000) Criteria for cure of acromegaly: a consensus statement. J Clin Endocrinol Metab 85:526-529
10. Giustina A, Chanson P, Bronstein MD, Klibanski A, Lamberts S, Casanueva FF, Trainer P, Ghigo E, Ho K, Melmed S, Acromegaly Consensus Group (2010) A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 95:3141-3148
11. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ (2002) Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 23:623-646
12. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF Jr, Montori VM, Endocrine Society (2008) Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 93:3266-3281
13. Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Schünemann HJ, GRADE Working Group (2008) GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 336:924-926
14. Kopchick JJ, List EO, Kelder B, Gosney ES, Berryman DE (2014) Evaluation of growth hormone (GH) action in mice: discovery of GH receptor antagonists and clinical indications. Mol Cell Endocrinol 386:34-45
15. Giustina A, Veldhuis JD (1998) Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr Rev 19:717-797
16. Mazziotti G, Giustina A (2013) Glucocorticoids and the regulation of growth hormone secretion. Nat Rev Endocrinol 9:265-276
17. Kamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P (2014) Growth hormone, insulin-like growth factor-1, and the kidney: pathophysiological and clinical implications. Endocr Rev 35:234-281
18. Ross RJM, Leung KC, Maamra M, Bennett W, Doyle N, Waters MJ, Ho KKY (2001) Binding and functional studies with the growth hormone receptor antagonist B2036-PEG (Pegvisomant), reveal effects of pegylation and evidence that it binds to a receptor dimer. J Clin Endocrinol Metab 86:1716-1723
19. de Vos AM, Ultsch M, Kossiakoff AA (1992) Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255:306-331
20. Carter-Su C, Rui L, Herrington J (2000) Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol 14:550-557
21. Muller AF, Kopchick JJ, Flyvbjerg A, Van Der Lely AJ (2004) Growth hormone receptor antagonists. J Clin Endocrinol Metab 89:1503-1511
22. Maamra M, Kopchick JJ, Strasburger CJ, Ross RJM (2004) Pegvisomant, a growth hormone-specific antagonist, undergoes cellular internalization. J Clin Endocrinol Metab 89:4532-4537
23. Colao A, Arnaldi G, Beck-Peccoz P, Cannavò S, Cozzi R, Degli Uberti E, De Marinis L, De Menis E, Ferone D, Gasco V, Giustina A, Grottoli S, Lombardi G, Maffei P, Martino E, Minuto F, Pivonello R, Ghigo E (2007) Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 30:693-699
24. Hodish I, Barkan A (2008) Long-term effects of Pegvisomant in patients with acromegaly. Nat Clin Pract Endocrinol Metab 4:324-332
25. Marazuela M, Paniagua AE, Gahete MD, Lucas T, Alvarez-Escolá C, Manzanares R, Cameselle-Teijeiro J, Luque-Ramirez M, Luque RM, Fernandez-Rodriguez E, Castaño JP, Bernabeu I (2011) Somatotroph tumor progression during Pegvisomant therapy: a clinical and molecular study. J Clin Endocrinol Metab 96:E251-E259
26. Colao A, Pivonello R, Auriemma RS, De Martino MC, Bidlingmaier M, Briganti F, Tortora F, Burman P, Kourides IA, Strasburger CJ, Lombardi G (2006) Efficacy of 12-month treatment with the GH receptor antagonist Pegvisomant in patients with acromegaly resistant to long-term, high-dose somatostatin analog treatment: effect on IGF-I levels, tumor mass, hypertension and glucose tolerance. Eur J Endocrinol 154:467-477
27. Neggers SJ, van Aken MO, de Herder WW, Feelders RA, Janssen JA, Badia X, Webb SM, van der Lely AJ (2008) Quality of life in acromegalic patients during long-term somatostatin analog treatment with and without Pegvisomant. J Clin Endocrinol Metab 93:3853-3859
28. Herman-Bonert VS, Zib K, Scarlett JA, Melmed S (2000) Growth hormone receptor antagonist therapy in acromegalic patients resistant to somatostatin analogs. J Clin Endocrinol Metab 85:2958-2961
29. Trainer PJ, Drake WM, Katznelson L, Freda PU, Herman-Bonert V, van der Lely AJ, Dimaraki EV, Stewart PM, Friend KE, Vance ML, Besser GM, Scarlett JA, Thorner MO, Parkinson C, Klibanski A, Powell JS, Barkan AL, Sheppard MC, Malsonado M, Rose DR, Clemmons DR, Johannsson G, Bengtsson BA, Stavrou S, Kleinberg DL, Cook DM, Phillips LS, Bidlingmaier M, Strasburger CJ, Hackett S, Zib K, Bennett WF, Davis RJ (2000) Treatment of acromegaly with the growth hormone-receptor antagonist Pegvisomant. N Engl J Med 342:1171-1177
30. van der Lely AJ, Hutson RK, Trainer PJ, Besser GM, Barkan AL, Katznelson L, Klibanski A, Herman-Bonert V, Melmed S, Vance ML, Freda PU, Stewart PM, Friend KE, Clemmons DR, Johannsson G, Stavrou S, Cook DM, Phillips LS, Strasburger CJ, Hackett S, Zib KA, Davis RJ, Scarlett JA, Thorner MO (2001) Long-term treatment of acromegaly with Pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759
31. Drake WM, Parkinson C, Akker SA, Monson JP, Besser GM, Trainer PJ (2001) Successful treatment of resistant acromegaly with a growth hormone receptor antagonist. Eur J Endocrinol 145:451-456
32. Barkan AL, Burman P, Clemmons DR, Drake WM, Gagel RF, Harris PE, Trainer PJ, van der Lely AJ, Vance ML (2005) Glucose homeostasis and safety in patients with acromegaly converted from long-acting octreotide to Pegvisomant. J Clin Endocrinol Metab 90:5684-5691
33. Schreiber I, Buchfelder M, Droste M, Forssmann K, Mann K, Saller B, Strasburger CJ, German Pegvisomant Investigators (2007) German Pegvisomant Investigators. Treatment of acromegaly with the GH receptor antagonist Pegvisomant in clinical practice: safety and efficacy evaluation from the German Pegvisomant Observational Study. Eur J Endocrinol 156:75-82
34. Higham CE, Chung TT, Lawranc J, Drake WM, Trainer PJ (2009) Long-term experience of Pegvisomant therapy as a treatment for acromegaly. Clin Endocrinol 71:86-91
35. Trainer PJ (2009) ACROSTUDY: the first 5 years. Eur J Endocrinol 161(Suppl 1):S19-S24
36. Buchfelder M, Schlaffer S, Droste M, Mann K, Saller B, Brübach K, Stalla GK, Strasburger CJ, German Pegvisomant Observational Study (2009) The German ACROSTUDY: past and present. Eur J Endocrinol 161(Suppl 1):S3-S10
37. Marazuela M, Lucas T, Alvarez-Escolá C, Puig-Domingo M, de la Torre NG, de Miguel-Novoa P, Duran-Hervada A, Manzanares R, Luque-Ramírez M, Halperin I, Casanueva FF, Bernabeu I (2009) Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist Pegvisomant: its efficacy in relation to gender and previous radiotherapy. Eur J Endocrinol 160:535-542
38. García Basavilbaso N, Guitelman M, Nagelberg A, Stalldecker G, Carabelli A, Bruno O, Danilowitz K, Manavela M, Mallea Gil S, Ballarino C, Guelman R, Katz D, Fidalgo S, Leal R, Fideleff H, Servidio M, Bruera D, Librandi F, Chervin A, Vitale M, Basso A (2010) Experience from the Argentine Pegvisomant Observational Study: preliminary data. Front Horm Res 38:42-49
39. van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M (2012) Long-term safety of Pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. J Clin Endocrinol Metab 97:1589-1597
40. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A (2006) Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 29:86-93
41. Parkinson C, Burman P, Messig M, Trainer PJ (2007) Gender, body weight, disease activity, and previous radiotherapy influence the response to Pegvisomant. J Clin Endocrinol Metab 92:190-195
42. Bianchi A, Giustina A, Cimino V, Pola R, Angelini F, Pontecorvi A, De Marinis L (2009) Influence of growth hormone receptor d3 and full-length isoforms on biochemical treatment outcomes in acromegaly. J Clin Endocrinol Metab 94:2015-2022
43. Bianchi A, Mazziotti G, Tilaro L, Cimino V, Veltri F, Gaetani E, Pecorini G, Pontecorvi A, Giustina A, De Marinis L (2009) Growth hormone receptor polymorphism and the effects of Pegvisomant in acromegaly. Pituitary 12:196-199
44. Bernabeu I, Alvarez-Escolá C, Quinteiro C, Lucas T, Puig-Domingo M, Luque-Ramírez M, de Miguel-Novoa P, Fernandez-Rodriguez E, Halperin I, Loidi L, Casanueva FF, Marazuela M (2010) The exon 3-deleted growth hormone receptor is associated with better response to Pegvisomant therapy in acromegaly. J Clin Endocrinol Metab 95:222-229
45. Filopanti M, Olgiati L, Mantovani G, Corbetta S, Arosio M, Gasco V, De Marinis L, Martini C, Bogazzi F, Cannavò S, Colao A, Ferone D, Arnaldi G, Pigliaru F, Peri A, Angeletti G, Jaffrain-Rea ML, Lania AG, Spada A (2012) Growth hormone receptor variants and response to Pegvisomant in monotherapy or in combination with somatostatin analogs in acromegalic patients: a multicenter study. J Clin Endocrinol Metab 97:E165-E172
46. Clemmons DR (2011) Consensus statement on the standardization and evaluation of growth hormone and insulin-like growth factor assays. Clin Chem 57:555-559
47. Milani D, Carmichael JD, Welkowitz J, Ferris S, Reitz RE, Danoff A, Kleinberg DL (2004) Variability and reliability of single serum IGF-I measurements: impact on determining predictability of risk ratios in disease development. J Clin Endocrinol Metab 89:2271-2274
48. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ (2007) Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol 67:65-70
49. Colao A, Ferone D, Marzullo P, Lombardi G (2004) Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 25:102-152
50. Clemmons DR (2004) The relative roles of growth hormone and IGF-1 in controlling insulin sensitivity. J Clin Invest 113:25-27
51. Mazziotti G, Floriani I, Bonadonna S, Torri V, Chanson P, Giustina A (2009) Effects of somatostatin analogs on glucose homeostasis: a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500-1508
52. Drake WM, Rowles SV, Roberts ME, Fode FK, Besser GM, Monson JP, Trainer PJ (2003) Insulin sensitivity and glucose tolerance improve in patients with acromegaly converted from depot octreotide to Pegvisomant. Eur J Endocrinol 149:521-527
53. Urbani C, Sardella C, Calevro A, Rossi G, Scattina I, Lombardi M, Lupi I, Manetti L, Martino E, Bogazzi F (2013) Effects of medical therapies for acromegaly on glucose metabolism. Eur J Endocrinol 169:99-108
54. Ghigo E, Biller BM, Colao A, Kourides IA, Rajicic N, Hutson RK, De Marinis L, Klibanski A (2009) Comparison of Pegvisomant and long-acting octreotide in patients with acromegaly naïve to radiation and medical therapy. J Endocrinol Invest 32:924-933
55. Lindberg-Larsen R, Møller N, Schmitz O, Nielsen S, Andersen M, Orskov H, Jørgensen JO (2007) The impact of Pegvisomant treatment on substrate metabolism and insulin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724-1728
56. Higham CE, Rowles S, Russell-Jones D, Umpleby AM, Trainer PJ (2009) Pegvisomant improves insulin sensitivity and reduces overnight free fatty acid concentrations in patients with acromegaly. J Clin Endocrinol Metab 94:2459-2463
57. Rose DR, Clemmons DR (2002) Growth hormone receptor antagonist improves insulin resistance in acromegaly. Growth Horm IGF Res 12:418-424
58. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing Pegvisomant alone with combination therapy of Pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 71:549-557
59. Parkinson C, Drake WM, Wieringa G, Yates AP, Besser GM, Trainer PJ (2002) Serum lipoprotein changes following IGF-I normalization using a growth hormone receptor antagonist in acromegaly. Clin Endocrinol 56:303-311
60. Sesmilo G, Fairfield WP, Katznelson L, Pulaski K, Freda PU, Bonert V, Dimaraki E, Stavrou S, Vance ML, Hayden D, Klibanski A (2002) Cardiovascular risk factors in acromegaly before and after normalization of serum IGF-I levels with the GH antagonist Pegvisomant. J Clin Endocrinol Metab 87:1692-1699
61. Berg C, Petersenn S, Lahner H, Herrmann BL, Buchfelder M, Droste M, Stalla GK, Strasburger CJ, Roggenbuck U, Lehmann N, Moebus S, Jöckel KH, Möhlenkamp S, Erbel R, Saller B, Mann K, Investigative Group of the Heinz Nixdorf Recall Study and the German Pegvisomant Observational Study Board and Investigators (2010) Cardiovascular risk factors in patients with uncontrolled and long-term acromegaly: comparison with matched data from the general population and the effect of disease control. J Clin Endocrinol Metab 95:3648-3656
62. Colao A, Pivonello R, Grasso LF, Auriemma RS, Galdiero M, Savastano S, Lombardi G (2011) Determinants of cardiac disease in newly diagnosed patients with acromegaly: results of a 10 year survey study. Eur J Endocrinol 165:713-721
63. Pivonello R, Galderisi M, Auriemma RS, De Martino MC, Galdiero M, Ciccarelli A, D'Errico A, Kourides I, Burman P, Lombardi G, Colao A (2007) Treatment with growth hormone receptor antagonist in acromegaly: effect on cardiac structure and performance. J Clin Endocrinol Metab 92:476-482
64. Auriemma RS, Pivonello R, De Martino MC, Cudemo G, Grasso LF, Galdiero M, Perone Y, Colao A (2012) Treatment with GH receptor antagonist in acromegaly: effect on cardiac arrhythmias. Eur J Endocrinol 168:15-22
65. De Martino MC, Auriemma RS, Brevetti G, Vitale G, Schiano V, Galdiero M, Grasso L, Lombardi G, Colao A, Pivonello R (2010) The treatment with growth hormone receptor antagonist in acromegaly: effect on vascular structure and function in patients resistant to somatostatin analogues. J Endocrinol Invest 33:663-670
66. Giustina A, Mazziotti G, Canalis E (2008) Growth hormone, insulin-like growth factors, and the skeleton. Endocr Rev 29:535-559
67. Mazziotti G, Bianchi A, Bonadonna S, Nuzzo M, Cimino V, Fusco A, De Marinis L, Giustina A (2006) Increased prevalence of radiological spinal deformities in adult patients with GH deficiency: influence of GH replacement therapy. J Bone Miner Res 21:520-528
68. Bonadonna S, Mazziotti G, Nuzzo M, Bianchi A, Fusco A, De Marinis L, Giustina A (2005) Increased prevalence of radiological spinal deformities in active acromegaly: a cross-sectional study in postmenopausal women. J Bone Miner Res 20:1837-1844
69. Mazziotti G, Gola M, Bianchi A, Porcelli T, Giampietro A, Cimino V, Doga M, Gazzaruso C, De Marinis L, Giustina A (2011) Influence of diabetes mellitus on vertebral fractures in men with acromegaly. Endocrine 40:102-108
70. Mazziotti G, Bianchi A, Porcelli T, Mormando M, Maffezzoni F, Cristiano A, Giampietro A, De Marinis L, Giustina A (2013) Vertebral fractures in patients with acromegaly: a 3-year prospective study. J Clin Endocrinol Metab 98:3402-3410
71. Fairfield WP, Sesmilo G, Katznelson L, Pulaski K, Freda PU, Stavrou S, Kleinberg D, Klibanski A (2002) Effects of a growth hormone receptor antagonist on bone markers in acromegaly. Clin Endocrinol 57:385-390
72. Parkinson C, Kassem M, Heickendorff L, Flyvbjerg A, Trainer PJ (2003) Pegvisomant-induced serum insulin-like growth factor-I normalization in patients with acromegaly returns elevated markers of bone turnover to normal. J Clin Endocrinol Metab 88:5650-5655
73. Jimenez C, Ayala-Ramirez M, Liu J, Nunez R, Gagel RF (2011) Inhibition of growth hormone receptor activation by Pegvisomant may increase bone density in acromegaly. Horm Metab Res 43:55-61
74. Colao A, Auriemma RS, Lombardi G, Pivonello R (2011) Resistance to somatostatin analogs in acromegaly. Endocr Rev 32:247-271
75. Murray RD, Melmed S (2008) A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab 93:2957-2968
76. Howlett TA, Willis D, Walker G, Wass JAH, Trainer PJ, UK Acromegaly Register Study Group (UKAR-3) (2013) Control of growth hormone and IGF1 in patients with acromegaly in the UK: responses to medical treatment with somatostatin analogues and dopamine agonists. Clin Endocrinol 79:689-699
77. Carmichael JD, Bonert VS, Nuno M, Ly D, Melmed S (2014) Acromegaly clinical trial methodology impact on reported biochemical efficacy rates of somatostatin receptor ligand treatments: a meta-analysis. J Clin Endocrinol Metab 99:1825-1833
78. Amato G, Mazziotti G, Rotondi M, Iorio S, Doga M, Sorvillo F, Manganella G, Di Salle F, Giustina A, Carella C (2002) Long-term effects of lanreotide SR and octreotide LAR on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly. Clin Endocrinol 56:65-71
79. Mazziotti G, Giustina A (2010) Effects of lanreotide SR and Autogel on tumor mass in patients with acromegaly: a systematic review. Pituitary 13:60-67
80. Giustina A, Mazziotti G, Torri V, Spinello M, Floriani I, Melmed S (2012) Meta-analysis on the effects of octreotide on tumor mass in acromegaly. PLoS ONE 7:e36411
81. Salenave S, Boyce AM, Collins MT, Chanson P (2014) Acromegaly and McCune-Albright syndrome. J Clin Endocrinol Metab 99(6):1955-1969
82. Colao A, Attanasio R, Pivonello R, Cappabianca P, Cavallo LM, Lasio G, Lodrini A, Lombardi G, Cozzi R (2006) Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 91:85-92
83. Thorner MO, Strasburger CJ, Wu Z, Straume M, Bidlingmaier M, Pezzoli SS, Zib K, Scarlett JC, Bennett WF (1999) Growth hormone (GH) receptor blockade with a PEG-modified GH (B2036-PEG) lowers serum insulin-like growth factor-I but does not acutely stimulate serum GH. J Clin Endocrinol Metab 84:2098-2103
84. SOMAVERT EPAR: Available at this URL: http://www.ema.europa.eu/docs/enGB/documentlibrary/EPAR-Summaryforthepublic/human/000409/WC500054622.pdf
85. Jen J, LaBadie RR, Liang Y, Crownover PH, Gao X, Hey-Hadavi JH (2013) Pegvisomant bioavability of single30 mg/ml subcutaneous injection compared to two 15 mg/ml subcutaneous injections: a pharmacokinetic, safety and tolerability study. Growth Horm IGF Res 23:114-119
86. Marazuela M, Ramos-Leví A, Sampedro-Núñez M, Bernabeu I (2014) Cabergoline treatment in acromegaly: pros. Endocrine 46:215-219
87. Kasuki L, Vieira Neto L, Gadelha MR (2014) Cabergoline treatment in acromegaly: cons. Endocrine 46:220-225
88. Higham CE, Atkinson AB, Aylwin S, Bidlingmaier M, Drake WM, Lewis A, Martin NM, Moyes V, Newell-Price J, Trainer PJ (2012) Effective combination treatment with cabergoline and low-dose Pegvisomant in active acromegaly: a prospective clinical trial. J Clin Endocrinol Metab 97:1187-1193
89. Bernabeu I, Alvarez-Escolá C, Paniagua AE, Lucas T, Pavón I, Cabezas-Agrícola JM, Casanueva FF, Marazuela M (2013) Pegvisomant and cabergoline combination therapy in acromegaly. Pituitary 16:101-108
90. Feenstra J, de Herder WW, ten Have SM, van den Beld AW, Feelders RA, Janssen JA, van der Lely AJ (2005) Combined therapy with somatostatin analogues and weekly Pegvisomant in active acromegaly. Lancet 365:1644-1646
91. Neggers SJ, van Aken MO, Janssen JA, Feelders RA, de Herder WW, van der Lely AJ (2007) Long-term efficacy and safety of combined treatment of somatostatin analogs and Pegvisomant in acromegaly. J Clin Endocrinol Metab 92:4598-4601
92. van der Lely AJ, Bernabeu I, Cap J, Caron P, Colao A, Marek J, Neggers S, Birman P (2011) Coadministration of lanreotide Autogel and Pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone. Eur J Endocrinol 164:325-333
93. Jørgensen JO, Feldt-Rasmussen U, Frystyk J, Chen JW, Kristensen LØ, Hagen C, Ørskov H (2005) Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631
94. Leung KC, Doyle N, Ballesteros M, Waters MJ, Ho KK (2000) Insulin regulation of human hepatic growth hormone receptors: divergent effects on biosynthesis and surface translocation. J Clin Endocrinol Metab 85:4712-4720
95. Bianchi A, Valentini F, Iuorio R, Poggi M, Baldelli R, Passeri M, Giampietro A, Tartaglione L, Chiloiro S, Appetecchia M, Gargiulo P, Fabbri A, Toscano V, Pontecorvi A, De Marinis L (2013) Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with Pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes. J Exp Clin Cancer Res 32:40
96. De Marinis L, Bianchi A, Fusco A, Cimino V, Mormando M, Tilaro L, Mazziotti G, Pontecorvi A, Giustina A (2007) Long-term effects of the combination of Pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patients with active acromegaly partially resistant to SSA. Pituitary 10:227-232
97. Bonert VS, Kennedy L, Petersenn S, Barkan A, Carmichael J, Melmed S (2008) Lipodystrophy in patients with acromegaly receiving Pegvisomant. J Clin Endocrinol Metab 93:3515-3518
98. Maffei P, Martini C, Pagano C, Sicolo N, Corbetti F (2006) Lipohypertrophy in acromegaly induced by the new growth hormone receptor antagonist Pegvisomant. Ann Intern Med 145:310-312
99. Biering H, Saller B, Bauditz J, Pirlich M, Rudolph B, Johne A, Buchfelder M, Mann K, Droste M, Schreiber I, Lochs H, Strasburger CJ (2006) Elevated transaminases during medical treatment of acromegaly: a review of the German Pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis. Eur J Endocrinol 154:213-220
100. Neggers SJ, de Herder WW, Janssen JA, Feelders RA, van der Lely AJ (2009) Combined treatment for acromegaly with long-acting somatostatin analogs and Pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients. Eur J Endocrinol 160:529-533
101. Feenstra J, Van Aken MO, de Herder WW, Feelders RA, Van der Lely AJ (2006) Drug-induced hepatitis in an acromegalic patient during combined treatment with Pegvisomant and octreotide long-acting repeatable attributed to the use of Pegvisomant. Eur J Endocrinol 154:805-806
102. Trainer PJ, Ezzat S, D'Souza GA, Layton G, Strasburger CJ (2009) A randomized, controlled, multicentre trial comparing Pegvisomant alone with combination therapy of Pegvisomant and long-acting octreotide in patients with acromegaly. Clin Endocrinol 71:549-557
103. Madsen M, Poulsen PL, Ørskov H, Møller N, Jørgensen JOL (2011) Cotreatment with Pegvisomant and a Somatostatin Analog (SA) in SA-Responsive Acromegalic Patients. J Clin Endocrinol Metab 96:2405-2413
104. Bernabeu I, Marazuela M, Lucas T, Loidi L, Alvarez-Escolá C, Luque-Ramírez M, Fernandez-Rodriguez E, Paniagua AE, Quinteiro C, Casanueva FF (2010) Pegvisomant-induced liver injury is related to the UGT1A128 polymorphism of Gilbert's syndrome. J Clin Endocrinol Metab 95:2147-2154
105. Jimenez C, Burman P, Abs R, Clemmons DR, Drake WM, Hutson KR, Messig M, Thorner MO, Trainer PJ, Gagel RF (2008) Follow-up of pituitary tumor volume in patients with acromegaly treated with Pegvisomant in clinical trials. Eur J Endocrinol 159:517-523
106. Buchfelder M, Weigel D, Droste M, Mann K, Saller B, Brubach K, Stalla GK, Bidlingmaier M, Strasburger CJ (2009) Pituitary tumor size in acromegaly during Pegvisomant treatment: experience from MR re-evaluations of the German Pegvisomant Observational Study. Eur J Endocrinol 161:27-35
107. Buhk JH, Jung S, Psychogios MN, Goricke S, Hartz S, Schulz-Heise S, Klingebiel R, Forsting M, Bruckmann H, Dorfler A, Jordan M, Buchfelder M, Knauth M (2010) Tumor volume of growth hormone secreting pituitary adenomas during treatment with Pegvisomant: a prospective multicenter study. J Clin Endocrinol Metab 95:552-558
108. Jehle S, Reyes CM, Sundeen RE, Freda PU (2005) Alternate-day administration of Pegvisomant maintains normal serum insulin-like growth factor-i levels in patients with acromegaly. J Clin Endocrinol Metab 90:1588-1593
109. Brian SR, Bidlingmaier M, Wajnrajch MP, Weinzimer SA, Inzucchi SE (2007) Treatment of acromegaly with Pegvisomant during pregnancy: maternal and fetal effects. J Clin Endocrinol Metab 92:3374-3377
110. Didoni G, Grottoli S, Gasco V, Battistini M, Ferone D, Giusti M, Ragazzoni F, Ruffo P, Ghigo E, Minuto F (2004) Cost-of-illness study in acromegalic patients in Italy. J Endocrinol Invest 27:1034-1039
111. Ben-Shlomo A, Sheppard MC, Stephens JM, Pulgar S, Melmed S (2011) Clinical, quality of life, and economic value of acromegaly disease control. Pituitary 14:284-294
112. Moore DJ, Adi Y, Connock MJ, Bayliss S (2009) Clinical effectiveness and cost-effectiveness of Pegvisomant for the treatment of acromegaly: a systematic review and economic evaluation. BMC Endocrinol Disorder 9:20
113. De Marinis L, Bonadonna S, Bianchi A, Maira G, Giustina A (2005) Primary empty sella. J Clin Endocrinol Metab 90:5471-5477
114. Sandret L, Maison P, Chanson P (2011) Place of cabergoline in acromegaly: a meta-analysis. J Clin Endocrinol Metab 96:1325-1335
115. Giustina A, Karamouzis I, Patelli I, Mazziotti G (2013) Octreotide for acromegaly treatment: a reappraisal. Expert Opin Pharmacother 14:2433-2447
116. Maison P, Tropeano AI, Macquin-Mavier I, Giustina A, Chanson P (2007) Impact of somatostatin analogs on the heart in acromegaly: a metaanalysis. J Clin Endocrinol Metab 92:1743-1747